Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Pentobarbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.47 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentobarbital SCHEMBL6489504 | 0.93 | CYP3A4 (0.49) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL2689394 | 0.93 | CYP3A4 (0.49) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL2769858 | 0.92 | CYP3A4 (0.51) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL2715148 | 0.91 | CYP3A4 (0.48) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL3474760 | 0.91 | CYP3A4 (0.48) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL2824790 | 0.91 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL477033 | 0.91 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL16174651 | 0.91 | CYP3A4 (0.53) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL22290963 | 0.91 | CYP3A4 (0.45) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL15900299 | 0.90 | CYP3A4 (0.47) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| CN-110741015-B | Compositions and methods for treating and/or preventing pathogenic fungal infections and maintaining microbiota symbiosis | 芝加哥大学 | 2023-08-25 | — | — | CN | disclosed |
| WO-2020063628-A1 | GLP1-FC FUSION PROTEIN AND CONJUGATE THEREOF | 北京辅仁瑞辉生物医药研究院有限公司 | 2020-04-02 | — | — | WO | disclosed |
| US-9422349-B2 | N-terminal modified exendin-4 | HANMI SCIENCE CO., LTD (KR) | 2016-08-23 | — | — | US | disclosed |
| EP-2537860-B1 | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | HANMI SCIENCE CO LTD (KR) | 2014-11-26 | — | — | EP | disclosed |
| EP-2537861-B1 | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | HANMI SCIENCE CO LTD (KR) | 2014-11-26 | — | — | EP | disclosed |
| EP-2390265-B1 | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | HANMI SCIENCE CO LTD (KR) | 2013-11-06 | — | — | EP | disclosed |
| EP-2537861-A1 | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | Hanmi Science Co., Ltd. (KR) | 2012-12-26 | — | — | EP | disclosed |
| EP-2537860-A1 | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | Hanmi Science Co., Ltd. (KR) | 2012-12-26 | — | — | EP | disclosed |
| EP-2390265-A2 | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | Hanmi Holdings Co., Ltd. (KR) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257645-A1 | SYSTEMS AND METHODS FOR TREATING A HOLLOW ANATOMICAL STRUCTURE | TYCO HEALTHCARE GROUP LP (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2347762-A1 | Exendin for treating diabetes and reducing body weight | AMYLIN PHARMACEUTICALS, INC. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100204451-A1 | INSULINOTROPIC PEPTIDE DERIVATIVE WHEREIN ITS N-TERMINAL AMINO ACID IS MODIFIED | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2010-08-12 | — | — | US | disclosed |
| EP-2176289-A2 | INSULINOTROPIC PEPTIDE DERIVATIVE WHEREIN ITS N-TERMINAL AMINO ACID IS MODIFIED | Hanmi Pharmaceutical Co., Ltd. (KR) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009011544-A2 | INSULINOTROPIC PEPTIDE DERIVATIVE WHEREIN ITS N-TERMINAL AMINO ACID IS MODIFIED | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204451-A1 | INSULINOTROPIC PEPTIDE DERIVATIVE WHEREIN ITS N-TERMINAL AMINO ACID IS MODIFIED | IAPP, GLP1R, GPR119 | GABRB3 1569/4885GABRA2 1163/4885GABRB2 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.